+919998510543
Downloads
Online IPO
Online KYC
e-KYC
+919998510543
Back Office Login
Live Trading
Send "Hi" to get your Back Office details.
Click Here -
https://wa.me/+919998510543
x
Home
About Us
Market
Equity
IPO
Derivatives
Currency Derivative
Authorised Person
Install Dealer Terminal
Data from Year 2022-23 onward
Historical Data from 2017-18 to 2022-23
Historical Data from 2010-11 to 2016-17
List of AP
Client
Install Solo Terminal
Data from Year 2022-23 onward
Historical Data from 2017-18 to 2022-23
Historical Data from 2010-11 to 2016-17
Install ACMP PRO Android Mobile App
Install ACMP PRO iPhone Mobile App
COLLATERAL INFORMATION
6 KYC Updation
NSDL E-VOTING
CDSL E-Voting
NSDL Nomination Online
NSDL e-Services
NSDL – Online Account Closure cum Transfer Request
ACML Announcement
Event
communique
Announcement
Contact us
CAREERS
Home
About Us
Market
Equity
IPO
Derivatives
Currency Derivative
Authorised Person
Install Dealer Terminal
Data from Year 2022-23 onward
Historical Data from 2017-18 to 2022-23
Historical Data from 2010-11 to 2016-17
List of AP
Client
Install Solo Terminal
Data from Year 2022-23 onward
Historical Data from 2017-18 to 2022-23
Historical Data from 2010-11 to 2016-17
Install ACMP PRO Android Mobile App
Install ACMP PRO iPhone Mobile App
COLLATERAL INFORMATION
6 KYC Updation
NSDL E-VOTING
CDSL E-Voting
NSDL Nomination Online
Announcement
communique
Announcement
Contact us
CAREERS
IPO
Home
IPO
IPO Synopsis
Forthcoming IPO
Open IPO
Close IPO
New Listing
Basis of Allotment
Draft Prospectus
New Issue Monitor
IPO Synopsis
Gland Pharma Ltd
Registered Office:
Sy No 143-148 150&151 Nr Gandi,X Roads D P Pally Dundigal , Hyderabad - 500043 , Telangana , India.
Phone : 91-40-30510999 Fax:91-40-30510800
Email :
investors@glandpharma.com
Website :
www.glandpharma.com
Initial public offer of 43196968 equity shares of face value of Re. 1 each ("equity shares") of Gland Pharma Limited ("Company" or "Issuer") for cash at a price of Rs.1500 Per equity share (including a share premium of Rs.1499 per equity share) aggregating Rs.6479.55 crores (The "Offer") comprising a fresh issue of 8,333,333 equity shares aggregating up to Rs. 1250 crores on (The "fresh issue") and an offer for sale of 34,863,635 equity shares, including 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd ("promoter selling shareholder") and 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Limited, 3,573,014 equity shares By Empower Discretionary Trust, and 1,874,500 equity shares by Nilay Discretionary Trust (collectively, the "other selling shareholders" and collectively With the promoter selling shareholder are referred to as the "selling shareholders", and such equity shares, the "offered shares") aggregating up to Rs. 5229.55 crores (the "offer for sale"). The offer shall constitute 26.46% of the post-offer paid-up equity share capital of the company. The face value of Equity shares is Re.1 each. The offer price is Rs.1500 per equity share and is 1500 times the face value of the Equity Shares. The Anchor Investor Offer Price is Rs.1500 per Equity Share.
Issue
Money Payable On
Opens On
Closes On
Application
Allotment
09-Nov-20
11-Nov-20
R
s
1500.00-0.00
R
s
0.00-0.00
Minimum Application for shares in Nos :10 Further Multiples of :10
R
s
Cr
Lead Managers to the Issue
Project Cost
1250.00
Citigroup Global Markets India Pvt Ltd
Project Financed through Current Offer
6479.55
Post Issue Equity Share Capital
163.28
Issue Price
R
s
1500.00
Projects
Funding incremental working capital requirements of the company
General corporate purposes
Funding capital expenditure requirements of the company
Promoted By
Fosun Pharma Indust. Pte. Ltd
Shanghai Fosun Pharma. Group
Listing At
BSE
NSE
Registrar to the Issue
Link Intime India Pvt Ltd